Literature DB >> 7176660

Biotransformation rate (in vitro) and systemic potency (in vivo) of the topical glucocorticoid budesonide in male and female rats.

P Andersson, R Brattsand, S Edsbäcker, L Källström, A Ryrfeldt.   

Abstract

Budesonide is a glucocorticoid of clinical interest for the topical treatment of skin and respiratory diseases. The in vitro liver biotransformation rate and in vivo systemic potency (thymus involution) of budesonide were studied in male and female rats. The biotransformation rate of [3H]-budesonide was about 4 times slower in the female than in the male rat liver 9000 g supernatant (t 1/2; 230 and 57 min, respectively). The systemic potency of budesonide after peroral or subcutaneous administration was higher (by factors of 6 and 2, respectively) in the female than in the male rat. These results suggest that the liver biotransformation rate of budesonide is of great importance in reducing its systemic action in the male rat.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7176660     DOI: 10.1016/0022-4731(82)90574-x

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  3 in total

1.  Pharmacokinetics of budesonide in children with asthma.

Authors:  S Pedersen; G Steffensen; I Ekman; M Tönnesson; O Borgå
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Human liver budesonide sulphotransferase is inhibited by testosterone and correlates with by testosterone sulphotransferase.

Authors:  G M Pacifici; M A Ferroni; A Temellini; A Gucci; M C Morelli; L Giuliani
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 3.  Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis.

Authors:  S P Clissold; R C Heel
Journal:  Drugs       Date:  1984-12       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.